Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-04-24

Clinical Trial Update: Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating chemotherapy followed by Zevalin (ibritumomab tiuxetan) for relapsed mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED